公开(公告)号：US20240192224A1

公开(公告)日：2024-06-13

申请号：US18553490

申请日：2022-04-01

Applicant: ADITXT, INC.

Inventor： Ge CHEN ,  Hong LIU ,  Shahrokh SHABAHANG

IPC: G01N33/68 ,  G01N33/543 ,  G01N33/569 ,  G01N33/58

CPC classification number: G01N33/6854 ,  G01N33/54313 ,  G01N33/56983 ,  G01N33/582 ,  G01N2469/20 ,  G01N2470/10

Abstract: The present disclosure relates generally to compositions and methods for assaying antibodies. More specifically, the disclosure relates to assays that detect antibodies that have neutralizing activity against SARS-CoV-2.

公开(公告)号：US20240352469A1

公开(公告)日：2024-10-24

申请号：US18687772

申请日：2022-08-26

Applicant: ADITXT, INC.

Inventor： Marco PALIZA-CARRE ,  Shahrokh SHABAHANG ,  Ge CHEN

IPC: C12N15/117 ,  A61K39/00

CPC classification number: C12N15/117 ,  A61K39/0008 ,  A61K39/001 ,  A61K39/0011 ,  A61K2039/53

Abstract: The present disclosure provides a method of enzymatically methylating a DNA by combining a source DNA encoding a pro-apoptotic protein, a determinant protein, or a functional fragment thereof, an extracellular methylation enzyme and an enzymatic substrate in an amount sufficient to allow methylation of at least one CpG site on the source DNA and then incubating the reaction sample at a temperature and for a time sufficient to obtain an enzymatically methylated DNA having a specific methylation level or a specific methylation pattern. The disclosure further provides enzymatically methylated DNA, pharmaceutical compositions containing enzymatically methylated DNA, and methods of treatment using such enzymatically methylated DNA or pharmaceutical compositions.

公开(公告)号：US20240016905A1

公开(公告)日：2024-01-18

申请号：US17909705

申请日：2021-03-03

Applicant: Aditxt, Inc. ,  THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Inventor： Shahrokh SHABAHANG ,  David ALLEVA ,  Avnesh S. THAKOR

IPC: A61K39/00 ,  A61P3/10

CPC classification number: A61K39/0008 ,  A61P3/10 ,  A61K2039/577 ,  A61K2039/53 ,  A61K2039/55561

Abstract: Methods of reversing hyperglycemia and suppressing diabetes onset in a patient at risk of developing type 1 diabetes are provided. In particular, a vector system comprising a first expression cassette encoding BCL2 associated X apoptosis regulator (BAX) and a hypermethylated second expression cassette encoding a secreted glutamic acid decarboxylase 65 (sGAD55) are administered to the patient to induce a tolerogenic response.